On September 16, 2019, as part of the IV annual BIOTECHMED Biotechnology Forum, Teva and FSUE “Moscow Endocrine Plant” signed a Memorandum of Intent to implement actions aimed at introducing the Trizenox drug (arsenic trioxide) to the Russian market for the treatment of acute promyelocytic leukemia in adult patients with resistance to retinoids and chemotherapeutic drugs.
According to the Memorandum, the parties will study the possibility of transferring from Teva to FSUE “Moscow Endocrine Plant” the rights of the holder of the Registration Certificate and the rights to import, sell, distribute, and also promote the drug in the territory of the Russian Federation. The purpose of the partnership is to ensure accessibility for patients in the Russian Federation of the drug Trizenox (arsenic trioxide), intended to achieve remission in patients with acute promyelocytic leukemia.
“We are seeing an increase in the demand of the Russian health care system for effective high-quality orphan drugs. Trizenox is a really important drug that will provide an opportunity for Russian patients to receive timely treatment with proven clinical efficacy and good tolerance to such rare cancer as acute promyelocytic leukemia. The signing of the Memorandum of Intent is a strategically important step for the company, and we will make every effort to ensure the timely transfer of rights and improve the provision of our patients with the drug,”
commented Eric Roche, Teva CEO in Russian Federation.